Cancers (May 2024)

Radiotherapy Plan Quality Assurance in NRG Oncology Trials for Brain and Head/Neck Cancers: An AI-Enhanced Knowledge-Based Approach

  • Du Wang,
  • Huaizhi Geng,
  • Vinai Gondi,
  • Nancy Y. Lee,
  • Christina I. Tsien,
  • Ping Xia,
  • Thomas L. Chenevert,
  • Jeff M. Michalski,
  • Mark R. Gilbert,
  • Quynh-Thu Le,
  • Antonio M. Omuro,
  • Kuo Men,
  • Kenneth D. Aldape,
  • Yue Cao,
  • Ashok Srinivasan,
  • Igor J. Barani,
  • Sean Sachdev,
  • Jiayi Huang,
  • Serah Choi,
  • Wenyin Shi,
  • James D. Battiste,
  • Zabi Wardak,
  • Michael D. Chan,
  • Minesh P. Mehta,
  • Ying Xiao

DOI
https://doi.org/10.3390/cancers16112007
Journal volume & issue
Vol. 16, no. 11
p. 2007

Abstract

Read online

The quality of radiation therapy (RT) treatment plans directly affects the outcomes of clinical trials. KBP solutions have been utilized in RT plan quality assurance (QA). In this study, we evaluated the quality of RT plans for brain and head/neck cancers enrolled in multi-institutional clinical trials utilizing a KBP approach. The evaluation was conducted on 203 glioblastoma (GBM) patients enrolled in NRG-BN001 and 70 nasopharyngeal carcinoma (NPC) patients enrolled in NRG-HN001. For each trial, fifty high-quality photon plans were utilized to build a KBP photon model. A KBP proton model was generated using intensity-modulated proton therapy (IMPT) plans generated on 50 patients originally treated with photon RT. These models were then applied to generate KBP plans for the remaining patients, which were compared against the submitted plans for quality evaluation, including in terms of protocol compliance, target coverage, and organ-at-risk (OAR) doses. RT plans generated by the KBP models were demonstrated to have superior quality compared to the submitted plans. KBP IMPT plans can decrease the variation of proton plan quality and could possibly be used as a tool for developing improved plans in the future. Additionally, the KBP tool proved to be an effective instrument for RT plan QA in multi-center clinical trials.

Keywords